Nevertheless, 80–85% of Jak2 V617F negative MPN patients can be diagnosed with a recently discovered distinct frame-shift mutation in exon 9 of the calreticulin (CALR) gene [7, 8] which weakens Ca2 + binding affinity of CALR [9, 10]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.